1998
DOI: 10.5694/j.1326-5377.1998.tb140229.x
|View full text |Cite|
|
Sign up to set email alerts
|

Positron emission tomography In assessing response to neoadjuvant chemotherapy for non‐small‐cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2000
2000
2007
2007

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 4 publications
0
3
0
Order By: Relevance
“…In 22 patients with advanced breast cancer, changes in FDG uptake were able to predict the eventual histopathologic response with an accuracy of 88% after the first course of drugs and 91% after the second course [ 76 ]. Similar utility has been described in cancers of the lung [ 77 ] and colon [ 78 ], as well as Hodgkin's [ 79 ] and non-Hodgkin's lymphoma [ 80 ].…”
Section: Imagingmentioning
confidence: 55%
“…In 22 patients with advanced breast cancer, changes in FDG uptake were able to predict the eventual histopathologic response with an accuracy of 88% after the first course of drugs and 91% after the second course [ 76 ]. Similar utility has been described in cancers of the lung [ 77 ] and colon [ 78 ], as well as Hodgkin's [ 79 ] and non-Hodgkin's lymphoma [ 80 ].…”
Section: Imagingmentioning
confidence: 55%
“…6). 2,7,14,46 The timing and reliability of 18 F-FDG PET studies in predicting tumour response are the subjects of numerous prospective studies at present. The implications of this approach are significant in terms of optimizing treatment regimens, minimizing unnecessary morbidity and reducing costs.…”
Section: Monitoring Response Of Tumour To Therapymentioning
confidence: 99%
“…6). 2,7,14,46 The timing and reliability of 18 F‐FDG PET studies in predicting tumour response are the subjects of numerous prospective studies at present. The implications of this approach are significant in terms of optimizing treatment regimens, minimizing unnecessary morbidity and reducing costs.…”
Section: Monitoring Response Of Tumour To Therapymentioning
confidence: 99%